Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s treatment for classic galactosemia.

The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...

The deal suggests Roche sees substantial promise in Poseida’s technology, as the offer is 215% above the biotech’s closing ...

Long-awaited results released Tuesday showed adding tiragolumab to Roche's immunotherapy Tecentriq did not extend survival in ...

Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...

Dublin/Frankfurt, 27 November, 2024 - Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing ...

Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC ...

Millions of Americans who have obesity could gain insurance coverage for drugs like Wegovy if the Trump administration allows the rule to go into effect.

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.